Proteros launches new cryo-EM facility to speed drug discovery
MUNICH, Sept. 8, 2020 /PRNewswire/ -- The new Center of Excellence will focus on technologically challenging targets, building on Proteros' strength in protein science and heritage in protein crystallography and represents another step towards making cryo-EM a routine industrial application in drug discovery. Proteros is collaborating with Thermo Fisher Scientific to develop the experimental methods, protein sample preparation processes and workflows. The collaboration combines the capabilities of two leaders in the field of cryo-EM and will accelerate the pace at which new pharmaceutical drugs can be brought to market.
Proteros also announced the formation of a cryo-EM consortium that will offer industry partners dedicated access to microscope time and preferred access to Proteros' protein science capabilities. Membership will provide hands on cryo-EM training, data processing and interpretation sessions.
Dr. Stephan Krapp, Director Structural Biology at Proteros commented "Customers will benefit from our expertise in protein science and an experienced cryo-EM team, including expertise in protein crystallography. This initiative will advance cryo-EM toward routine application in drug discovery by enabling the study of proteins not accessible by x-ray crystallography."
The Proteros cryo-EM facility will feature a Thermo Scientific Glacios Cryo-TEM with advanced Falcon 4 direct electron detector and will be co-located at Proteros' Munich headquarters alongside the Protein Sciences department. Proteros has one of the largest dedicated Protein Sciences teams staffed with more than 50 experts enabling it to deliver fit for purpose protein constructs of the highest quality.
"Collaborating with Proteros to meet the cryo-EM needs of customers will accelerate biopharmaceutical research and development and will also encourage more scientists to embrace cryo-EM for their drug discovery research," said Raymond Schrijver, senior director of electron microscopy for pharma at Thermo Fisher. "Cryo-EM is taking structure-based drug design into a new era, and the rapid adoption of this technique will have a direct impact on drug discovery and medical treatments."
Cryo-EM customers will benefit from Proteros' scientific insight and problem-solving approach for difficult drug discovery targets. Onsite capabilities in protein production, sample preparation and compound characterization produce more accurate results, quickly allowing drug developers to make better informed decisions to advance their discovery programs.
Proteros, Martinsried/Munich, Germany is a private biotechnology company providing drug discovery support for technically demanding drug targets. Proteros is currently working for most of the big pharma and biotech companies in Europe, US and Japan providing a wide variety of service and collaborative relationships.
For more information please visit www.proteros.com
For additional information please contact:
Dr. Stephan Krapp, Director Structural Biology
Proteros biostructures GmbH
View original content to download multimedia:http://www.prnewswire.com/news-releases/proteros-launches-new-cryo-em-facility-to-speed-drug-discovery-301126054.html
SOURCE Proteros Biostructures GmbH